Key result
Mineralocorticoid receptor antagonists reduce morbidity and mortality in patients with heart failure and reduced ejection fraction, and prevent cardiac remodeling and fibrosis.
Why the study?
Do mineralocorticoid receptor antagonists provide clinical benefits in patients with heart failure and cardiovascular disease?
Do mineralocorticoid receptor antagonists provide clinical benefits in patients with heart failure and cardiovascular disease?
This review highlights the established efficacy of MRAs in HFrEF and discusses their potential benefits in HFpEF, arrhythmias, and ischemic heart disease.
No takes yet. Share an insight, caveat, or question.
Supports MRA use in HFrEF; leaves open benefits in HFpEF, arrhythmias, and ischemic disease pending prospective trials.
Vizzardi et al. (2014) conducted a review in Heart failure. Mineralocorticoid receptor antagonists (MRAs) was evaluated. Mineralocorticoid receptor antagonists reduce morbidity and mortality in patients with heart failure and reduced ejection fraction, and prevent cardiac remodeling and fibrosis.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: